Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Clinical trial NCT06161545 · RECRUITING

Trial details

NCT number: NCT06161545
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stage II Squamous Cell Carcinoma of the Head and Neck Stage III Squamous Cell Carcinoma of the Head and Neck Stage IV Squamous Cell Carcinoma of the Head and Neck

Start date: 2025-09-24
Primary completion: 2026-12-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.